Ascrinvacumab
Experimental monoclonal antibody
Ascrinvacumab is an experimental monoclonal antibody (mAb) that is being investigated for its potential therapeutic applications. Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. They can be designed to target specific cells or proteins, making them useful in the treatment of various diseases, including cancer, autoimmune diseases, and infectious diseases.
Mechanism of Action[edit | edit source]
Ascrinvacumab works by targeting a specific antigen found on the surface of certain cells. By binding to this antigen, the antibody can either directly inhibit the function of the target cell or mark it for destruction by other components of the immune system. The exact mechanism of action for ascrinvacumab is still under investigation, but it is believed to involve the modulation of immune responses.
Clinical Trials[edit | edit source]
Ascrinvacumab is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are essential for determining the potential therapeutic benefits and risks associated with the drug. The results of these trials will determine whether ascrinvacumab can be approved for use in clinical practice.
Potential Applications[edit | edit source]
The primary focus of research on ascrinvacumab is its application in the treatment of various types of cancer. Monoclonal antibodies like ascrinvacumab can be used to target cancer cells specifically, reducing the impact on healthy cells and minimizing side effects. Additionally, there is ongoing research into its potential use in treating autoimmune diseases and infectious diseases.
Side Effects[edit | edit source]
As with any therapeutic agent, ascrinvacumab may have side effects. Common side effects associated with monoclonal antibodies include infusion reactions, allergic reactions, and immunosuppression. The specific side effects of ascrinvacumab will be better understood as clinical trials progress.
See Also[edit | edit source]
References[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
